Efficacy of Bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: a randomized placebo-controlled clinical trial
-
Published:2024-01-03
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Zhang QiORCID, Li Guang, Zhao WenORCID, Wang XifanORCID, He JingjingORCID, Zhou LimianORCID, Zhang XiaoxuORCID, An PengORCID, Liu YinghuaORCID, Zhang ChengyingORCID, Zhang YongORCID, Liu Simin, Zhao LiangORCID, Liu RongORCID, Li Yixuan, Jiang Wenjian, Wang XiaoyuORCID, Wang QingyuORCID, Fang BingORCID, Zhao YuyangORCID, Ren YimeiORCID, Niu XiaokangORCID, Li DongjieORCID, Shi ShaoqiORCID, Hung Wei-LianORCID, Wang RanORCID, Liu XinjuanORCID, Ren FazhengORCID
Abstract
AbstractCurrent treatment for functional dyspepsia (FD) has limited and unsustainable efficacy. Probiotics have the sustainable potential to alleviate FD. This randomized controlled clinical trial (Chinese Clinical Trial Registry, ChiCTR2000041430) assigned 200 FD patients to receive placebo, positive-drug (rabeprazole), or Bifidobacterium animalis subsp. lactis BL-99 (BL-99; low, high doses) for 8-week. The primary outcome was the clinical response rate (CRR) of FD score after 8-week treatment. The secondary outcomes were CRR of FD score at other periods, and PDS, EPS, serum indicators, fecal microbiota and metabolites. The CRR in FD score for the BL-99_high group [45 (90.0%)] was significantly higher than that for placebo [29 (58.0%), p = 0.001], BL-99_low [37 (74.0%), p = 0.044] and positive_control [35 (70.0%), p = 0.017] groups after 8-week treatment. This effect was sustained until 2-week after treatment but disappeared 8-week after treatment. Further metagenomic and metabolomics revealed that BL-99 promoted the accumulation of SCFA-producing microbiota and the increase of SCFA levels in stool and serum, which may account for the increase of serum gastrin level. This study supports the potential use of BL-99 for the treatment of FD.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference44 articles.
1. Tack, J. & Talley, N. J. Functional dyspepsia-symptoms, definitions and validity of the Rome III criteria. Nat. Rev. Gastroenterol. Hepatol. 10, 134–141 (2013). 2. Ford, A. C., Marwaha, A., Sood, R. & Moayyedi, P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 64, 1049–1057 (2015). 3. Sayuk, G. S. & Gyawali, C. P. Functional dyspepsia: diagnostic and therapeutic approaches. Drugs 80, 1319–1336 (2020). 4. Stanghellini, V. et al. Gastroduodenal disorders. Gastroenterology 150, 1380–1392 (2016). 5. Ford, A. C., Forman, D., Bailey, A. G., Axon, A. T. & Moayyedi, P. Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am. J. Gastroenterol. 107, 912–921 (2012).
|
|